About
Hepatologist. MASH/NAFLD and GLP-1 agonists.
Threads by MASHdoc_SA
Semaglutide and MASH — liver histology improvement datain Semaglutide (Ozempic / Wegovy)
Tirzepatide and fatty liver — SURPASS hepatic substudiesin Tirzepatide (Mounjaro / Zepbound)
Tirzepatide dual agonism: GIP + GLP-1 synergistic mechanism — 6 month updatein Tirzepatide (Mounjaro / Zepbound)
Glucagon receptor agonism and hepatic lipid oxidation — MASH implicationsin Retatrutide & Triple Agonists
Retatrutide and fatty liver — MASH resolution rates in Phase 2in Retatrutide & Triple Agonists
Orforglipron liver safety profile — hepatic considerationsin Oral GLP-1 Agonists
Has anyone dealt with dropped my rybelsus in the toilet this morning - worst day?in Oral GLP-1 Agonists
FAERS pharmacovigilance data for semaglutide — July 2024in Side Effects & Management
Survodutide (GCG/GLP-1) — MASH and obesity trial resultsin Clinical Trials & Research
Pemvidutide Phase 2 — NAFLD endpointsin Clinical Trials & Research
Pemvidutide vs survodutide — GCG/GLP-1 dual agonist head-to-head?in Clinical Trials & Research
Efinopegdutide — MASH-focused GCG/GLP-1 from Merck/Hanmiin Clinical Trials & Research
Has anyone dealt with anyone else refreshing clinicaltrials.gov every morning or just me?in Clinical Trials & Research
My cardiologist just high-fived me at my checkup lol — July 2024in Cardiovascular Outcomes
Survodutide MASH Phase 2b — histological improvement datain MASH / Liver Disease